ArticleOncotarget2019

Failures in preclinical and clinical trials of c-Met inhibitors: evaluation of pathway activity as a promising selection criterion.

Veronica S Hughes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.